208 related articles for article (PubMed ID: 35491133)
1. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events.
Hayashi H; Sawada K; Hasebe T; Nakajima S; Sawada J; Takiyama Y; Takiyama Y; Okumura T; Fujiya M
Intern Med; 2022 Dec; 61(23):3497-3502. PubMed ID: 35491133
[TBL] [Abstract][Full Text] [Related]
2. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furuichi N; Naganuma A; Kaburagi T; Suzuki Y; Hoshino T; Shibusawa N; Horiguchi S; Hatanaka T; Kakizaki S; Uraoka T
Clin J Gastroenterol; 2023 Jun; 16(3):422-431. PubMed ID: 36821067
[TBL] [Abstract][Full Text] [Related]
3. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Fukushima T; Morimoto M; Kobayashi S; Ueno M; Uojima H; Hidaka H; Kusano C; Chuma M; Numata K; Tsuruya K; Arase Y; Kagawa T; Hattori N; Ikeda H; Watanabe T; Tanaka K; Maeda S
Oncologist; 2023 Jul; 28(7):e526-e533. PubMed ID: 37023703
[TBL] [Abstract][Full Text] [Related]
4. Isolated Adrenocorticotropic Hormone Deficiency Associated with Atezolizumab and Bevacizumab Administration for Treating Hepatocellular Carcinoma: A Case Series.
Ikeda Y; Sato S; Omu R; Nishimura A; Arii S; Uchida R; Nomura K; Sato S; Murata A; Shimada Y; Genda T
Intern Med; 2023 Nov; 62(22):3341-3346. PubMed ID: 37032085
[TBL] [Abstract][Full Text] [Related]
5. Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma.
Fukushima M; Tajima K; Sasaki R; Nakao Y; Takahashi K; Ozawa E; Miuma S; Kato T; Miyaaki H; Nakao K
Clin J Gastroenterol; 2023 Jun; 16(3):402-406. PubMed ID: 36746879
[TBL] [Abstract][Full Text] [Related]
6. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
[TBL] [Abstract][Full Text] [Related]
7. A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.
Iwasaki S; Hidaka H; Uojima H; Hashimura M; Nabeta T; Sanoyama I; Wada N; Kubota K; Nakazawa T; Shibuya A; Koizumi W
Clin J Gastroenterol; 2021 Aug; 14(4):1233-1239. PubMed ID: 34024039
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
10. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
[TBL] [Abstract][Full Text] [Related]
11. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis.
Fukunaga A; Takata K; Itoh S; Yamauchi R; Tanaka T; Yokoyama K; Shakado S; Kohashi K; Yoshizumi T; Hirai F
Clin J Gastroenterol; 2023 Apr; 16(2):224-228. PubMed ID: 36495383
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
Özdirik B; Jost-Brinkmann F; Savic LJ; Mohr R; Tacke F; Ploner CJ; Roderburg C; Müller T
Medicine (Baltimore); 2021 Jun; 100(24):e26377. PubMed ID: 34128898
[TBL] [Abstract][Full Text] [Related]
13. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
[TBL] [Abstract][Full Text] [Related]
15. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y
Cancer Med; 2023 Apr; 12(7):7772-7783. PubMed ID: 36518086
[TBL] [Abstract][Full Text] [Related]
16. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
18. Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment.
Takakusagi S; Tanaka H; Naganuma A; Kakizaki S; Shibuya K; Ohno T; Takagi H; Uraoka T
Clin J Gastroenterol; 2023 Jun; 16(3):407-415. PubMed ID: 36750524
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab-associated myositis in a patient with unresectable hepatocellular carcinoma.
Baigi T; Brown EN; De La Torre RM; Abu-Shahin FI
J Oncol Pharm Pract; 2023 Oct; 29(7):1757-1761. PubMed ID: 37282559
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
